Hormonal
Activation of Sirt1 via exercise or Sirt1-activating compounds (e.g., resveratrol, SRT3025) delays vascular aging and reduces atherosclerosis by enhancing antioxidant enzyme activity and improving endothelial nitric oxide synthase (eNOS) function.
Engage in regular physical exercise, which naturally boosts Sirt1 activity by increasing NAD+ levels. This helps maintain vascular health and may delay age-related cardiovascular decline. While supplements like resveratrol are marketed for this purpose, human evidence is inconsistent, making exercise the most reliable intervention.
Sirt1 is considered an interesting target to delay vascular aging through its antioxidant properties. In fact, it increases the activity of catalase and induces manganese superoxide dismutase... Sirt1 modulates eNOS expression and activity... ApoE-/- mice fed for 12 weeks with a high-cholesterol diet supplemented with SRT3025, a pharmacological Sirt1 activator, showed reduced plasma levels of LDL and total cholesterol as well as reduced plaque formation.
Why this rating
Evidence is primarily from animal models (mice) and in vitro studies; clinical efficacy of synthetic activators is stated to require testing.
Source
Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease
Giovanni G. Camici et al. · European Heart Journal · 2015
DOI 10.1093/eurheartj/ehv587
More from this paper
- Caloric restriction and exercise training delay the onset of age-associated diseases and decelerate aging effects via sirtuin-dependent pathways, including increased Sirt1 activity and reduced oxidative stress.Good
- Genetic deletion or silencing of the adaptor protein p66Shc reduces oxidative stress, improves endothelial function, and reduces stroke size in animal models, but may increase infarct size in specific myocardial ischemia-reperfusion contexts.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →